We apologize your item could not be found. Not all items are listed on our website. Please contact your account manager for details regarding your searched item.
Material number (eg: xxxxxxxxxxx) no space or hyphen needed.
No Results Found
The 2016 West without Borders campaign for Exton benefitted the Leukemia & Lymphoma Society (LLS)–the world’s largest voluntary health agency dedicated to finding a cure for blood cancers and providing essential support services for those affected by this disease.
West was a Presenting Sponsor for Eastern Pennsylvania’s October Light the Night Walks, which are an important part of LLS’s total fundraising efforts for research to find blood cancer cures. These inspirational and memorable walks bring together friends, family and community members to form fundraising walk teams. While walking, teams carry illuminated lanterns that represent their steps to end cancer. These lanterns honor cancer survivors and current patients, remember those we have lost, and emphasize the power of research towards finding a cure.
A total of 415 Exton employees, along with their families and friends, attended one of two Light the Night Walks in Chester County and Philadelphia, Pennsylvania. West’s total giving through our Presenting Sponsor investment, West without Borders Employee Giving Program, and individual fundraising through the LLS site was more than $336,000. West was the number one fundraising team at both the Chester County and Philadelphia walks!
West provided gifts for participants at the walks, including light-up shoelaces for children and glow-in-the-dark backpacks for all. The Exton team also created an activity center where children could write down their ‘secret’ wish and seal it in a West vial.
Thanks to all West employees and their guests for the generosity and enthusiasm shown at this year’s LLS Light the Night Walks.
West without Borders is not affiliated with Doctors Without Borders®, which is a registered service mark of Bureau International de Medecins San Frontieres.
West authors Diane Paskiet, Kim Miller, Laura Stubbs and Diego Zurbriggen contributed to several chapters in the new “Leachables and Extractables Handbook: Safety Evaluation, Qualification, and Best Practices Applied to Inhalation Drug Products” available from Wiley Scientific.
Cell and gene therapies are an expanding area with an expected growth rate of 24.7% over the forecast period of 2022-2030 .<sup>1</sup><br />Vial-stopper-seal combinations used as containment systems for these therapies need to maintain container closure integrity (CCI) for extended periods. Achieving CCI can be a particular challenge due to the low storage temperatures required: ultra-low (-80°C) for gene therapies and cryogenic (≤ -130°C, i.e., vapor of liquid nitrogen) for cell therapies.
In order to ensure the best quality drug product and optimal patient outcomes, it’s important for drug manufacturers to foster a collaborative effort with their packaging suppliers from the beginning – and that means starting with the patient in mind. Understanding patient needs and how that drug will be delivered, whether through one of West’s delivery devices or some other device, will help determine the needs within the West manufacturing process.
When left untreated, diabetes eventually can lead to a variety of issues for patients, including complications such as stroke, blindness and heart and/or kidney disease. In addition, adherence to painful or inconvenient injection treatments can be difficult for patients, with as many at 57% of Type 1 and Type 2 diabetes patients admitting to intentionally skipping injections.<sup>1</sup>
West employees have forged a strong bond with many of the local organizations they support through the West without Borders fundraising initiative.
English
Chinese
